Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.53 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 8/20 | 0.49 |
| ▸ | ACHE | P22303 | 8/20 | 0.49 |
| ▸ | BACE1 | P56817 | 8/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817642 | 0.88 | ACHE (0.52) | NPFFR1NPFFR2BCHEACHEBACE1 | |
| SCHEMBL2824751 | 0.87 | CCR2 (0.49) | NPFFR1NPFFR2BCHEACHEBACE1 | |
| SCHEMBL2276952 | 0.82 | FKBP1A (0.54) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A | |
| SCHEMBL28345021 | 0.81 | NPFFR1 (0.79) | NPFFR1NPFFR2KMT2AMEN1CYP3A4 | |
| SCHEMBL24938939 | 0.81 | CYP3A4 (0.50) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A | |
| SCHEMBL5368566 | 0.81 | CYP3A4 (0.50) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A | |
| SCHEMBL19853295 | 0.81 | ALDH1A1 (0.47) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A | |
| SCHEMBL15325590 | 0.81 | CYP3A4 (0.50) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A | |
| SCHEMBL4249938 | 0.81 | CYP3A4 (0.50) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A | |
| SCHEMBL19408855 | 0.81 | CYP3A4 (0.50) | KMT2ACYP3A4KDM4EALDH1A1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155672-B1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-2155672-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| US-7528136-B2 | for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile | HOFFMANN-LA ROCHE INC. (US) | 2009-05-05 | — | — | US | disclosed |
| WO-2008148689-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-11 | — | — | WO | disclosed |
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306086-A1 | PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS | SLC6A3, OPRL1, OPRK1 | NPFFR1 32/4885NPFFR2 24/4885BCHE 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.